Voyager Therapeutics Lands $60,000,000 Series B Funding

  • Feed Type
  • Date
    4/13/2015
  • Company Name
    Voyager Therapeutics
  • Mailing Address
    75 Sidney St. Cambridge, MA 02139 USA
  • Company Description
    Voyager Therapeutics is developing life-changing gene therapies for fatal and debilitating diseases of the central nervous system. Our founders include scientific and clinical leaders in the fields of adeno-associated virus (AAV) gene therapy, expressed RNA interference and neuroscience.
  • Website
    http://www.voyagertherapeutics.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $60,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Proceeds from the financing will be used to advance the company’s product pipeline, which includes five clinical and preclinical programs, as well as its industry-leading adeno-associated virus (AAV) product engine.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy